English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Forty-three years after it was founded, with billions of dollars invested, the global biotech industry is still not positioned as a mature low-risk sector for the international investor com-munity. Despite the clear commercial success of a number of leading companies and overall growth of the industry's rev-enues, most biotech companies are not profi table and many fail to overcome the formidable barrier constituted by the high cost of the sector's research and development. However, over the last four years, visible signs of change have appeared, which could be harbingers of an approaching turning point in this trend.This article analyzes the historic background of the biotech in-dustry's business models and corporate structures, as well as their impact on the industry's fi nancial framework. It examines recent changes implemented by the sector's main actors-in-cluding young startups, venture capital funds and big pharma companies-to mitigate fi nancial risk associated with develop-ment of new biotechnology products.Finally, it discusses the challenges and opportunities that these tendencies entail for Cuban biotechnology development and proposes adoption of business policies more tolerant of the fi nancial risk inherent in this sector, as a condition for at-tracting venture capital. KEYWORDS Biotechnology, fund raising, risk management, entrepreneurship, Cuba.

Role of Business Models in Funding the Biotech Industry: Global Trends and Challenges for Cuban Biotechnology